Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation

[1]  L. Kristensen,et al.  Epigenetics and cancer treatment. , 2009, European journal of pharmacology.

[2]  K. Tikoo,et al.  5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. , 2009, Toxicology letters.

[3]  E. Ricevuto,et al.  Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. , 2009, International journal of oncology.

[4]  Vincenza Dolo,et al.  Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. , 2009, Endocrine-related cancer.

[5]  M. Yashiro,et al.  DNA methyltransferase inhibitor 5‐aza‐CdR enhances the radiosensitivity of gastric cancer cells , 2009, Cancer science.

[6]  W. Dewey,et al.  Arrhenius relationships from the molecule and cell to the clinic , 2009, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[7]  Hui Wang,et al.  c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells , 2008, PloS one.

[8]  Xin Wu,et al.  HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells , 2008, PloS one.

[9]  A. Spencer,et al.  The effect of azacitidine on interleukin-6 signaling and nuclear factor-κB activation and its in vitro and in vivo activity against multiple myeloma , 2008, Haematologica.

[10]  Vincenza Dolo,et al.  Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen‐independent prostate cancer cells , 2008, The Prostate.

[11]  A. C. Santos,et al.  Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver , 2008, Journal of applied toxicology : JAT.

[12]  P. Nguyen,et al.  DNMT1 as a Molecular Target in a Multimodality-Resistant Phenotype in Tumor Cells , 2008, Molecular Cancer Research.

[13]  H. Donninger,et al.  The RASSF1A tumor suppressor , 2007, Journal of Cell Science.

[14]  M. Maio,et al.  Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications , 2007, Journal of cellular physiology.

[15]  D. Chauhan,et al.  5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells , 2007, Molecular Cancer Therapeutics.

[16]  D. Spitz,et al.  2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. , 2007, Cancer research.

[17]  S. Sang,et al.  Possible controversy over dietary polyphenols: benefits vs risks. , 2007, Chemical research in toxicology.

[18]  A. Spencer,et al.  PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. , 2007, Blood.

[19]  M. Tainsky,et al.  Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin. , 2007, Cancer research.

[20]  J. Issa,et al.  Decitabine--bedside to bench. , 2007, Critical reviews in oncology/hematology.

[21]  A. Thorne,et al.  Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis , 2007, Cell Death and Differentiation.

[22]  Jian Li,et al.  PTEN augments doxorubicin‐induced apoptosis in PTEN‐null Ishikawa cells , 2006, International Journal of Gynecologic Cancer.

[23]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[24]  S. Fulda,et al.  5-Aza-2′-deoxycytidine and IFN-γ cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8 , 2006, Oncogene.

[25]  E. Borden,et al.  Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. T. Su,et al.  Ionizing radiation induces caspase-dependent but Chk2- and p53-independent cell death in Drosophila melanogaster. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Bradley R. Cairns,et al.  Chromatin remodelling: the industrial revolution of DNA around histones , 2006, Nature Reviews Molecular Cell Biology.

[28]  M. Piris,et al.  Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. , 2006, Cancer research.

[29]  R. Isbrucker,et al.  Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[30]  C. Peterson,et al.  Heterochromatin assembly: A new twist on an old model , 2006, Chromosome Research.

[31]  E. Borden,et al.  Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. , 2006, Cancer research.

[32]  F. Lyko,et al.  Reactivation of Epigenetically Silenced Genes by DNA Methyltransferase Inhibitors: Basic Concepts and Clinical Applications , 2006, Epigenetics.

[33]  S. Sang,et al.  Redox properties of tea polyphenols and related biological activities. , 2005, Antioxidants & redox signaling.

[34]  L. Ricci-Vitiani,et al.  Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. , 2005, Cancer research.

[35]  Chi-Tang Ho,et al.  Synthesis and structure identification of thiol conjugates of (-)-epigallocatechin gallate and their urinary levels in mice. , 2005, Chemical research in toxicology.

[36]  J. Vialard,et al.  p53-Independent Regulation of p21Waf1/Cip1 Expression and Senescence by Chk2 , 2005, Molecular Cancer Research.

[37]  Cameron Neylon,et al.  Replication Termination in Escherichia coli: Structure and Antihelicase Activity of the Tus-Ter Complex , 2005, Microbiology and Molecular Biology Reviews.

[38]  P. Malfertheiner,et al.  Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. , 2005, International journal of oncology.

[39]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[40]  J. Olson,et al.  Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer , 2005, Oncogene.

[41]  A. Vecchione,et al.  Myc Down-Regulation Sensitizes Melanoma Cells to Radiotherapy by Inhibiting MLH1 and MSH2 Mismatch Repair Proteins , 2005, Clinical Cancer Research.

[42]  Kazuhiko Aoyagi,et al.  Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. , 2005, Cancer research.

[43]  M. Azuma,et al.  Expression of aquaporin-5 in and fluid secretion from immortalized human salivary gland ductal cells by treatment with 5-aza-2′-deoxycytidine: a possibility for improvement of xerostomia in patients with Sjögren's syndrome , 2005, Laboratory Investigation.

[44]  K. Hahm,et al.  Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity , 2005, Nature Cell Biology.

[45]  L. Harris,et al.  Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. , 2005, Molecular cancer therapeutics.

[46]  S. Lees-Miller,et al.  Doxorubicin Activates ATM-dependent Phosphorylation of Multiple Downstream Targets in Part through the Generation of Reactive Oxygen Species* , 2004, Journal of Biological Chemistry.

[47]  D. Ginzinger,et al.  The ATM gene is a target for epigenetic silencing in locally advanced breast cancer , 2004, Oncogene.

[48]  Li Mao,et al.  Hypermethylation of the death-associated protein kinase promoter attenuates the sensitivity to TRAIL-induced apoptosis in human non-small cell lung cancer cells. , 2004, Molecular cancer research : MCR.

[49]  P. M. Das,et al.  DNA methylation and cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  W. Linehan,et al.  The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2′-deoxycytidine , 2004, Clinical Cancer Research.

[51]  A. Jeltsch,et al.  Biochemistry and biology of mammalian DNA methyltransferases , 2004, Cellular and Molecular Life Sciences CMLS.

[52]  C. Fegan,et al.  The Novel Sequence-Specific DNA Cross-Linking Agent SJG-136 (NSC 694501) Has Potent and Selective In vitro Cytotoxicity in Human B-Cell Chronic Lymphocytic Leukemia Cells with Evidence of a p53-Independent Mechanism of Cell Kill , 2004, Cancer Research.

[53]  G. Schwartz,et al.  Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe , 2004, Cancer Research.

[54]  J. Roth,et al.  5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells , 2004, Oncogene.

[55]  Paul Lizardi,et al.  Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells , 2004, Molecular and Cellular Biology.

[56]  Gangning Liang,et al.  Preferential response of cancer cells to zebularine. , 2004, Cancer cell.

[57]  I. Flinn,et al.  Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. Rippe,et al.  Peroxisome Proliferator-activated Receptor γ Induces a Phenotypic Switch from Activated to Quiescent Hepatic Stellate Cells* , 2004, Journal of Biological Chemistry.

[59]  S. Weitzman,et al.  Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer , 2004, Cancer Research.

[60]  R. Kerbel,et al.  Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. , 2004, Molecular cancer therapeutics.

[61]  L. Ellis,et al.  Activator Protein 2α Inhibits Tumorigenicity and Represses Vascular Endothelial Growth Factor Transcription in Prostate Cancer Cells , 2004, Cancer Research.

[62]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[63]  K. Somasundaram,et al.  Cell Cycle Arrest and Apoptosis Induction by Activator Protein 2α (AP-2α) and the Role of p53 and p21WAF1/CIP1 in AP-2α-mediated Growth Inhibition* , 2003, Journal of Biological Chemistry.

[64]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[65]  J. Issa,et al.  Comment on "Chromosomal Instability and Tumors Promoted by DNA Hypomethylation" and "Induction of Tumors in Mice by Genomic Hypomethylation" , 2003, Science.

[66]  D. Dickinson,et al.  Green Tea Polyphenol Causes Differential Oxidative Environments in Tumor versus Normal Epithelial Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[67]  Trevor Williams,et al.  Cloning and characterization of the mouse AP-2ε gene: a novel family member expressed in the developing olfactory bulb , 2003, Molecular and Cellular Neuroscience.

[68]  G. Luo,et al.  Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation , 2003, Oncogene.

[69]  Kai Rothkamm,et al.  Pathways of DNA Double-Strand Break Repair during the Mammalian Cell Cycle , 2003, Molecular and Cellular Biology.

[70]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[71]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[72]  M. Muller,et al.  Endogenous Assays of DNA Methyltransferases: Evidence for Differential Activities of DNMT1, DNMT2, and DNMT3 in Mammalian Cells In Vivo , 2003, Molecular and Cellular Biology.

[73]  K. Luger.  Structure and dynamic behavior of nucleosomes. , 2003, Current opinion in genetics & development.

[74]  Masayoshi Iizuka,et al.  Functional consequences of histone modifications. , 2003, Current opinion in genetics & development.

[75]  Jian Huang,et al.  Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. , 2003, Developmental biology.

[76]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[77]  B. Dunn.  Hypomethylation: One Side of a Larger Picture , 2003, Annals of the New York Academy of Sciences.

[78]  R. Weigel,et al.  Tumor Suppressor Activity of AP2α Mediated through a Direct Interaction with p53* , 2002, The Journal of Biological Chemistry.

[79]  R. G. Lloyd,et al.  Recombinational repair and restart of damaged replication forks , 2002, Nature Reviews Molecular Cell Biology.

[80]  P. Pohlmann,et al.  Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix , 2002, American journal of clinical oncology.

[81]  B. Evers,et al.  Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.

[82]  B. Turner,et al.  An increasingly complex code. , 2002, The Journal of clinical investigation.

[83]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[84]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[85]  R. Orlowski,et al.  NF-?B as a therapeutic target in cancer , 2002 .

[86]  W. H. Kim,et al.  Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers , 2002, British Journal of Cancer.

[87]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[88]  K. Brown,et al.  Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line , 2002, Oncogene.

[89]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Li Mao,et al.  Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[91]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[92]  M. Eilers,et al.  Contributions of Myc to tumorigenesis. , 2002, Biochimica et biophysica acta.

[93]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[94]  Michael M. Murphy,et al.  ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.

[95]  M. Jung,et al.  NF-κB signaling pathway as a target for human tumor radiosensitization , 2001 .

[96]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[97]  M. Arthur,et al.  Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells , 2001, Seminars in liver disease.

[98]  B. Michel,et al.  Rescue of arrested replication forks by homologous recombination , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[99]  V. Kosma,et al.  Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation , 2001, Journal of clinical pathology.

[100]  Jeffrey E Gershenwald,et al.  Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo , 2001, Oncogene.

[101]  C. Hunt,et al.  Increased activator protein 1 activity as well as resistance to heat-induced radiosensitization, hydrogen peroxide, and cisplatin are inhibited by indomethacin in oxidative stress-resistant cells. , 2001, Cancer research.

[102]  G. Stark,et al.  Regulation of the G2/M transition by p53 , 2001, Oncogene.

[103]  P. Marks,et al.  Inhibitors of histone deacetylase are potentially effective anticancer agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  D. Jones,et al.  Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. , 2001, Molecular pharmacology.

[105]  D. Durocher,et al.  DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.

[106]  R. Buettner,et al.  Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. , 2000, Gene.

[107]  Michael A Davies,et al.  MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells , 2000, Oncogene.

[108]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[109]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[110]  J. Tschopp,et al.  Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2000, Cancer research.

[111]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[112]  D. Cobrinik,et al.  Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. , 2000, Cancer letters.

[113]  V. Kosma,et al.  Expression of transcription factor AP-2α predicts survival in epithelial ovarian cancer , 2000, British Journal of Cancer.

[114]  J. Herman,et al.  CpG methylation is maintained in human cancer cells lacking DNMT1 , 2000, Nature.

[115]  A. Escargueil,et al.  Resistance mechanisms associated with altered intracellular distribution of anticancer agents. , 2000, Pharmacology & therapeutics.

[116]  H. Albertsen,et al.  Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[117]  J. Toretsky,et al.  Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. , 1999, Cancer research.

[118]  P. Koistinen,et al.  Protection of acute myeloblastic leukemia cells against apoptotic cell death by high glutathione and gamma-glutamylcysteine synthetase levels during etoposide-induced oxidative stress. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[120]  J. Herman,et al.  Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. , 1999, Blood.

[121]  W. Yung,et al.  Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. , 1999, Cancer research.

[122]  G. Evan,et al.  c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. , 1999, Genes & development.

[123]  N. Ahuja,et al.  Methylation and silencing of the Thrombospondin-1 promoter in human cancer , 1999, Oncogene.

[124]  R. Kerbel,et al.  Adhesion-dependent multicellular drug resistance. , 1999, Anti-cancer drug design.

[125]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[126]  G. Del Bino,et al.  Expression of HSP27 results in increased sensitivity to tumor necrosis factor, etoposide, and H2O2 in an oxidative stress‐resistant cell line , 1998, Journal of cellular physiology.

[127]  A. Perkins,et al.  AP-2-null cells disrupt morphogenesis of the eye, face, and limbs in chimeric mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[128]  A. Larsen,et al.  Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. , 1998, Biochimica et biophysica acta.

[129]  C. Hunt,et al.  Genomic instability and catalase gene amplification induced by chronic exposure to oxidative stress. , 1998, Cancer research.

[130]  Robert S. Kerbel,et al.  E-Cadherin–dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1 , 1998, The Journal of cell biology.

[131]  E. Li,et al.  Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases , 1998, Nature Genetics.

[132]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[133]  S. Baylin,et al.  Role of Estrogen Receptor Gene Demethylation and DNA Methyltransferase·DNA Adduct Formation in 5-Aza-2′deoxycytidine-induced Cytotoxicity In Human Breast Cancer Cells* , 1997, The Journal of Biological Chemistry.

[134]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[135]  J. Roth,et al.  Novel combination therapy for human colon cancer with adenovirus‐mediated wild‐type p53 gene transfer and DNA‐damaging chemotherapeutic agent , 1997, International journal of cancer.

[136]  D. Schadendorf,et al.  Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. , 1997, Anticancer research.

[137]  J. Bruce,et al.  Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.

[138]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[139]  Peter A. Jones,et al.  DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene , 1997, Oncogene.

[140]  C. Duhem,et al.  Multidrug resistance: molecular and clinical aspects. , 1997, Cytokines, cellular & molecular therapy.

[141]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[142]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[143]  R. Muschel,et al.  Potential molecular targets for manipulating the radiation response. , 1997, International journal of radiation oncology, biology, physics.

[144]  R. Kerbel,et al.  Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents , 1996, Nature Medicine.

[145]  R. Kerbel,et al.  Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. , 1996, Journal of the National Cancer Institute.

[146]  R. Roberts,et al.  Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts , 1995, Journal of cellular physiology.

[147]  Lin Qiu,et al.  Salicylate Triggers Heat Shock Factor Differently than Heat (*) , 1995, The Journal of Biological Chemistry.

[148]  R. Ozols,et al.  Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. , 1995, Cancer research.

[149]  A. Bhagwat,et al.  The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. , 1995, The Biochemical journal.

[150]  T. Curran,et al.  Zen and the art of Fos and Jun , 1995, Nature.

[151]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[152]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[153]  J. Roth,et al.  Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.

[154]  S. Friedman,et al.  Induction of EcoRII methyltransferase: evidence for autogenous control , 1993, Journal of bacteriology.

[155]  J. Phillips,et al.  Cellular resistance to oxidative stress is accompanied by resistance to cisplatin: The significance of increased catalase activity and total glutathione in hydrogen peroxide‐resistant fibroblasts , 1993, Journal of cellular physiology.

[156]  B. Teicher,et al.  Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[157]  A. Bhushan,et al.  Expression of c-fos in human and murine multidrug-resistant cells. , 1992, Molecular pharmacology.

[158]  R. Morimoto,et al.  Effect of sodium salicylate on the human heat shock response. , 1992, Science.

[159]  J. Haber,et al.  Two alternative pathways of double-strand break repair that are kinetically separable and independently modulated , 1992, Molecular and cellular biology.

[160]  B. Teicher,et al.  Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. , 1990, Science.

[161]  G. Li,et al.  Heat‐induced cytotoxicity in H2O2‐resistant Chinese hamster fibroblasts , 1990, Journal of cellular physiology.

[162]  R K Jain,et al.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.

[163]  L. Milas,et al.  Increase in radioresponse of murine tumors by treatment with indomethacin. , 1988, Cancer research.

[164]  S. Friedman,et al.  Survival and mutagenic effects of 5-azacytidine in Escherichia coli. , 1988, Mutation research.

[165]  David Baltimore,et al.  Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.

[166]  R. Guerrero,et al.  5-Azacytidine: survival and induction of the SOS response in Escherichia coli K-12. , 1986, Mutation research.

[167]  S. Friedman.  The irreversible binding of azacytosine-containing DNA fragments to bacterial DNA(cytosine-5)methyltransferases. , 1985, The Journal of biological chemistry.

[168]  D. Santi,et al.  Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[169]  Jack W. Szostak,et al.  The double-strand-break repair model for recombination , 1983, Cell.

[170]  P. Barr,et al.  On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs , 1983, Cell.

[171]  S. Gore,et al.  DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. , 2008, Seminars in hematology.

[172]  Leonhard Müllauer,et al.  Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. , 2008, Cancer research.

[173]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[174]  Dima Suki,et al.  Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[175]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[176]  R. Rippe,et al.  Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. , 2004, The Journal of biological chemistry.

[177]  Jing-Yuan Fang,et al.  5-Aza-2'-deoxycitydine induces demethylation and up-regulates transcription of p16INK4A gene in human gastric cancer cell lines. , 2004, Chinese medical journal.

[178]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[179]  R. Orlowski,et al.  NF-kappaB as a therapeutic target in cancer. , 2002, Trends in molecular medicine.

[180]  M. Jung,et al.  NF-kappa B signaling pathway as a target for human tumor radiosensitization. , 2001, Seminars in radiation oncology.

[181]  David A Jones,et al.  Activation of the p 53 DNA Damage Response Pathway after Inhibition of DNA Methyltransferase by 5-Aza-2 9-deoxycytidine , 2001 .

[182]  Laishun Chen,et al.  Human salivary tea catechin levels and catechin esterase activities: implication in human cancer prevention studies. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[183]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[184]  L. Nielsen,et al.  Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer , 1999, Cancer Chemotherapy and Pharmacology.

[185]  C. Hunt,et al.  Redox factor-1 (Ref-1) mediates the activation of AP-1 in HeLa and NIH 3T3 cells in response to heat shock. , 1999, The Journal of biological chemistry.

[186]  W. El-Deiry,et al.  AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression , 1997, Nature Genetics.

[187]  S. Bergelson,et al.  Intracellular glutathione levels regulate Fos/Jun induction and activation of glutathione S-transferase gene expression. , 1994, Cancer research.

[188]  R. Okayasu,et al.  Effects of hyperthermia on the repair of radiation-induced DNA single- and double-strand breaks in DNA double-strand break repair-deficient and repair-proficient cell lines. , 1990, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[189]  J. Dignam.  Preparation of extracts from higher eukaryotes. , 1990, Methods in enzymology.

[190]  D. Baltimore,et al.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. , 1986, Cell.